Alzheimer’s disease is the most common form of dementia and the sixth leading cause of death in the United States.
A chronic, progressive neurodegenerative disorder, Alzheimer’s usually develops slowly and can get worse over time. According to the Alzheimer’s Association, Alzheimer’s disease affects approximately 5.3 million people in the United States today and the number of patients afflicted with the disease is growing every year. By 2050, it is projected that the population living with Alzheimer’s disease over the age of 65 will approximate 14 million people.
Alzheimer’s Association Alzheimer’s Disease Facts and Figures 2014 and 2017; Barnes and Yaffe, Lancet Neurology, 2011 Sep; 10(9): 819-28
An estimated 80% of Alzheimer’s disease patients age 65 and older are classified as mild-to-moderate, which is the patient population we are focused on treating with intepirdine (RVT-101).
In 2017, total healthcare costs for Alzheimer’s and other dementias will cost $259 billion in the US alone. No new treatment options for patients have been approved by the FDA for the treatment of Alzheimer’s disease since 2003. Axovant is currently developing intepirdine in a Phase 3 international, multicenter, double-blind, placebo-controlled study designed to evaluate the safety, tolerability and efficacy intepirdine in mild-to-moderate Alzheimer’s disease patients called MINDSET study.
A global Phase 3 clinical research study evaluating intepirdine
(RVT-101)* for mild-to-moderate Alzheimer’s Disease
*Intepirdine (RVT-101) is an investigational new drug candidate and is not approved for any indication in any markets.